ATE437367T1 - Detektion und diagnose von übertragbaren spongiformen enzephalopathien - Google Patents

Detektion und diagnose von übertragbaren spongiformen enzephalopathien

Info

Publication number
ATE437367T1
ATE437367T1 AT03257981T AT03257981T ATE437367T1 AT E437367 T1 ATE437367 T1 AT E437367T1 AT 03257981 T AT03257981 T AT 03257981T AT 03257981 T AT03257981 T AT 03257981T AT E437367 T1 ATE437367 T1 AT E437367T1
Authority
AT
Austria
Prior art keywords
diagnosis
detection
spongiform encephalopathies
transmissable spongiform
transmissable
Prior art date
Application number
AT03257981T
Other languages
English (en)
Inventor
Jian Zheng
Steve Stanley Alexander
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Application granted granted Critical
Publication of ATE437367T1 publication Critical patent/ATE437367T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2872—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03257981T 2002-12-19 2003-12-18 Detektion und diagnose von übertragbaren spongiformen enzephalopathien ATE437367T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43462702P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
ATE437367T1 true ATE437367T1 (de) 2009-08-15

Family

ID=32508037

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03257981T ATE437367T1 (de) 2002-12-19 2003-12-18 Detektion und diagnose von übertragbaren spongiformen enzephalopathien

Country Status (8)

Country Link
EP (1) EP1435521B1 (de)
JP (1) JP4444644B2 (de)
AT (1) ATE437367T1 (de)
AU (1) AU2003266801B2 (de)
CA (1) CA2452946C (de)
DE (1) DE60328450D1 (de)
ES (1) ES2328027T3 (de)
PT (1) PT1435521E (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445615A1 (de) * 2003-02-10 2004-08-11 Ortho-Clinical Diagnostics, Inc. Methode zur unterscheidung zwischen infektiösen und nicht-infektiösen prionen
EP1668369B1 (de) 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitopschutztest und verfahren zum nachweis von proteinkonformationen
AU2005209592B2 (en) * 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
DK2514823T3 (en) 2006-03-03 2018-07-23 Promis Neurosciences Inc Methods and compositions for treating and detecting failed SOD1-mediated diseases
FR2973114A1 (fr) * 2011-03-21 2012-09-28 Ets Francais Du Sang Nanobilles recouvertes de plasminogene comme support direct d'amplification cyclique de la proteine prion prpsc

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806627A (en) * 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
EP0910408A4 (de) * 1996-03-08 2004-01-14 Univ California Darreichungssystem mit mab 3e10, mutanten und/oder funktionalen fragmenten davon
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen

Also Published As

Publication number Publication date
AU2003266801A1 (en) 2004-07-08
ES2328027T3 (es) 2009-11-06
JP2004198432A (ja) 2004-07-15
CA2452946A1 (en) 2004-06-19
PT1435521E (pt) 2009-08-27
CA2452946C (en) 2014-02-11
EP1435521A1 (de) 2004-07-07
DE60328450D1 (de) 2009-09-03
EP1435521B1 (de) 2009-07-22
AU2003266801B2 (en) 2010-02-25
JP4444644B2 (ja) 2010-03-31

Similar Documents

Publication Publication Date Title
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
CY1110606T1 (el) Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου
NL301089I2 (nl) imlifidase
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
DE60239931D1 (de) Kombinationstherapie
DE602004029034D1 (de) Replikin-peptide und anwendungen
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
CY1105266T1 (el) Αποστειρωση γλυκοκορτικοστepοειδων εναιωρηματων
WO2004044204A3 (fr) Fragments variables d'anticorps de camelides a chaine unique et leurs applications pour le diagnostic et le traitement de pathologies diverses.
DK2075007T3 (da) Behandling af Alzheimers sygdom
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
DE602004023201D1 (de) Antimikrobielle medizinprodukte
ES2179324T3 (es) Un metodo de deteccion de las encefalopatias espongiformes transmisibles.
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
WO2003049717A3 (en) Conductance of improperly folded proteins through the secretory pathway and related treatments of diseases
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
DE60328450D1 (de) Detektion und Diagnose von Übertragbaren Spongiformen Enzephalopathien
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
BR0010007A (pt) Indicadores biológicos para validação de um processo de esterilização de prìon
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE495269T1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
PL1756581T3 (pl) Sposób wykrywania prionu związanego z chorobą
EP1614428A4 (de) Arzneimittel zur vorbeugung oder behandlung angiogener augenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1435521

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1435521

Country of ref document: EP